Baxter receives European rMRP approval for Preflucel

Baxter has been granted approval for its seasonal influenza vaccine Preflucel under the European repeat mutual recognition procedure (rMRP).

The Austrian Agency for Health and Food Safety has given its endorsement to the treatment based on positive trial data showing its high level of protective efficacy and low adverse event profile.

This decision means the 13 EU states participating in the rMRP initiative – including the UK – will now assess the product on a national level, with an aim to making the treatment available for the 2011-12 influenza season.

Preflucel is composed of purified, inactivated split influenza virions and is manufactured using Baxter's innovative Vero cell technology, which allows for the use of the natural virus in its make-up.

Dr Hartmut Ehrlich, vice-president of global research and development for Baxter's bioscience business, said: "We are committed to offering our latest advancement in vaccine technology to effectively protect individuals and communities from seasonal influenza."

In January 2011, the company published its 2010 financial results, reporting a two percent annual sales growth and record cash flow levels.